<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>Science and Education Publishing</PublisherName>
<JournalTitle>Journal of Cancer Research and Treatment</JournalTitle>
<Issn>2374-2003</Issn>
<Volume>4</Volume>
<Issue>5</Issue>
<PubDate PubStatus="epublish">
<Year>2016</Year>
<Month>12</Month>
<Day>9</Day>
</PubDate>
</Journal>
<ArticleTitle>Diagnostic Utility of 18F-FDG PECT/CT in Assessment of Post-therapy Remission or Relapse of Lymphoma</ArticleTitle>
<FirstPage>88</FirstPage>
<LastPage>95</LastPage>
<Language>EN</Language>
<AuthorList>
<Author>
<FirstName>Nagham Nabil</FirstName>
<LastName>Omar</LastName>
</Author>
<Author>
<FirstName>Mostafa Shaker</FirstName>
<LastName>Abolela</LastName>
</Author>
<Author>
<FirstName>Marwa I.</FirstName>
<LastName>Abdelgawad</LastName>
<Affiliation>Clinical Oncology Department, Assiut University, Egypt</Affiliation>
</Author>
<Author>
<FirstName>Abeer</FirstName>
<LastName>Ibrahim</LastName>
</Author>
<Author>
<FirstName>Amr F.</FirstName>
<LastName>Mourad</LastName>
</Author>
<Author>
<FirstName>Khalid</FirstName>
<LastName>Rezk</LastName>
</Author>

</AuthorList>
<ArticleIdList>
<ArticleId IdType="pii">JCRT2016453</ArticleId>
<ArticleId IdType="doi">10.12691/jcrt-4-5-3</ArticleId>
</ArticleIdList>
<History>
<PubDate PubStatus="received">
<Year>2016</Year>
<Month>8</Month>
<Day>8</Day>
</PubDate>
<PubDate PubStatus="revised">
<Year>2016</Year>
<Month>10</Month>
<Day>26</Day>
</PubDate>
<PubDate PubStatus="accepted">
<Year>2016</Year>
<Month>12</Month>
<Day>7</Day>
</PubDate>
</History>
<Abstract>Background: Treatment and prognosis of lymphoma depend on accurate staging and evaluation. Relapsed Lymphomas represent great problem in accurate quick diagnosis that imply appropriate treatment. Aim of the work: To evaluate diagnostic utility of 18F-FDG PECT/CT in assessment of treatment response and identification of disease relapse. Patients and Methods: This prospective study were conducted on 49 consecutive patients with histologically verified lymphoma. They were 27/49 (55.1%) male and 22/49 (44.9%) female aged 37.83&#177;2.29. All patients were subjected to pretreatment as well a follow up clinical, laboratory, CT PET-CT. PET-CT findings were classified as positive and negative according to remission status and relapse. The sensitivity, specificity and accuracy of PET- CT in assessment of the remission status and relapse were calculated and to be confirmed by open or laparoscopic biopsy. Results: PET-CT detected complete regression in 28 patients (57.14%), partial regression in 4 patients (8.16%), stationary course in 2 patients (4.08%), progression / relapse in 15 patients (30.61%). According to PET/CT 9 (23%) patients were true positive, 25 (65%) were true negative and 5 (13%) were false negative with sensitivity, specificity, positive p predictive value and negative predictive value of 95% and 91%, 90% and 98%, respectively. Conclusion: Our results confirm FDG-PET as a valid tool for assessment of treatment response and detection of relapsing lymphoma. We recommended further multicentric prospective studies that incorporates a larger number of patients should be implemented to define the exact relation between certain clinical, pathological, laboratory and PET factors and fate of the disease.</Abstract>
</Article>
</ArticleSet>
